Skip to main content
SpringerLink
Log in

Development and Characterization of Enteric-Coated Immediate-Release Pellets of Aceclofenac by Extrusion/Spheronization Technique Using κ-Carrageenan as a Pelletizing Agent

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

In the present study, an attempt was made to prepare immediate-release enteric-coated pellets of aceclofenac, a poorly soluble nonsteroidal anti-inflammatory drug that has a gastrointestinal intolerance as its serious side effect. Formulation of enteric-coated pellets with improved solubility of aceclofenac could address both of these problems. To achieve these goals, pellets were prepared by extrusion–spheronization method using pelletizing agents that can contribute to the faster disintegration and thereby improve the solubility of the drug. Different disintegrants like β-cyclodextrin, kollidon CL, Ac-Di-Sol, and sodium starch glycolate were tried in order to further improve disintegration time. The pellets were characterized for drug content, particle size distribution, flow properties, infrared spectroscopy, surface morphology, disintegration rate, and dissolution profile. The formulations, which showed best disintegration and dissolution profiles, were coated with Eudragit L100-55, an enteric-coated polymer which does not dissolve at gastric pH but dissolves at intestinal pH, releasing the drug immediately in the dissolution medium. The optimized enteric-coated formulation containing 20% κ-carrageenan, lactose, and sodium starch glycolate as a disintegrant did inhibit the release of the drug for 2 h in 0.1 N HCl, whereas 87% of the drug was released within 45 min. The improvement was substantial when it was compared with solubility of pure drug under the same conditions. Thus, dissolution profiles suggested that combination of κ-carrageenan and sodium starch glycolate resulted into fast-disintegrating, immediate-release pellets, overcoming the bioavailability problem of the poorly soluble drug, aceclofenac, and enteric coating of these pellets avoids the exposure of aceclofenac to ulcer-prone areas of the gastrointestinal tract.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Parfitt K. Analgesic anti inflammatory and antipyretic. In: Reynolds JEF, editor. Martindale: The complete drug reference. 32nd ed. Taunton: Pharmaceutical Press; 1999. p. 2–12.

    Google Scholar 

  2. Yamazaki R, Kawai S, Mastsuzaki T, Kaneda N, Hashimoto S, Yokokura T, et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol. 1997;329:181–87.

    CAS  PubMed  Google Scholar 

  3. Franz M. Stabilized pharmaceutical compositions comprising an extended release nonsteroidal anti-inflammatory agent and immediate release prostaglandin. US Patent 7303761, December 4, 2007.

  4. Desai S, Nadkarni SR, Wald RJ, Debrincat GA. Dual release compositions of a cyclooxygenase-2 inhibitor. US Patent 7220434, May 22, 2007.

    Google Scholar 

  5. Yong CS, Oh YK, Lee KH, Park SM, Park YJ, Gil YS. Trials of clear aceclofenac-loaded soft capsules with accelerated oral absorption in human subjects. Int J Pharm. 2005;302:78–83.

    Article  CAS  PubMed  Google Scholar 

  6. Joshi VY, Sawant MR. Study on dissolution rate enhancement of poorly water soluble drug: contributions of solubility enhancement and relatively low micelle diffusivity. J Disp Sci Technol. 2006;27(8):1141–50.

    Article  CAS  Google Scholar 

  7. Dahiya S, Pathak K. Physicochemical characterization and dissolution enhancement of aceclofenac-hydroxypropyl beta-cyclodextrin binary systems. PDA J Pharm Sci Technol. 2006;60(6):378–88.

    CAS  PubMed  Google Scholar 

  8. Muatlik S, Usha AN, Reddy MS, Ranjith AK, Pandey S. Improved bioavailability of aceclofenac from spherical agglomerates: development, in vitro and preclinical studies. Pak J Pharm Sci. 2007;20(3):218–26.

    CAS  PubMed  Google Scholar 

  9. Mutalik S, Anju P, Manoj K, Usha AN. Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach. Int J Pharm. 2008;350(1–2):279–90.

    Article  CAS  PubMed  Google Scholar 

  10. Yesmin F, Talukder MMU, Islam MS, Laila S, Haque T. Evaluation of aceclofenac loaded agarose beads prepared by ionotropic gelation method. S J Pharm Sci. 2008;1(1&2):10–7.

    CAS  Google Scholar 

  11. Margret Chandira R, Venkataeswarlu BS, Kumudhavalli MV, Bhowmik D, Jayakar B. Formulation and evaluation of the fast dissolving tablets of aceclofenac. The Pharma Review. 2008; 164–67.

  12. Mallikarjuna Setty C, Prasad DVK, Gupta VRM, SA B. Development of fast dispersible aceclofenac tablets: effect of functionality of superdisintegrants. Ind Pharm Sci. 2008;70(2):180–5.

    Article  Google Scholar 

  13. Ghebre-Sellassie I. Pellets: a general overview. In: Ghebre-Sellassie I, editor. Pharmaceutical pelletization technology. New York: Marcel Dekker; 1989. p. 1–13. Vol.37.

    Google Scholar 

  14. Nassab PR, Rajkó R, Szabó-Révész P. Physicochemical characterization of meloxicam–mannitol binary systems. J Pharm Biomed Anal. 2006;41:1191–97.

    Article  CAS  PubMed  Google Scholar 

  15. O’Connor RE, Schwartz JB. Spheronization II: drug release from drug-diluent mixtures. Drug Dev Ind Pharm. 1985;11:1837–57.

    Article  Google Scholar 

  16. Thommes M, Kleinebudde P. Use of κ-carrageenan as alternative pelletization aid to microcrystalline cellulose in extrusion/spheronization, I: influence of type and fraction of filler. Eur J Pharm Biopharm. 2006;63:59–67.

    Article  CAS  PubMed  Google Scholar 

  17. Thommes M, Kleinebudde P. Use of κ-carrageenan as alternative pelletization aid to microcrystalline cellulose in extrusion/spheronization, II: influence of drug and filler type. Eur J Pharm Biopharm. 2006;63:68–75.

    Article  CAS  PubMed  Google Scholar 

  18. USP. The United States Pharmacopeia 2004 (USP 27). Toronto: Webcom Limited; 2003.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gurunanak College of Pharmacy, Khasra No. 81/1, Mauza Nari, Near Kamgaar Nagar, Behind C. P. Foundry, Kamptee Road, Nagpur, 440026, Maharashtra, India

    Vaishali A. Kilor & Nidhi P. Sapkal

  2. Department of Pharmaceutical Science, RTM Nagpur University Nagpur, Nagpur, Maharashtra, India

    Jasmine G. Awari

  3. H. R. Patel Women’s College of Pharmacy, Karwand Naka, Tal-Shirpur, 425405, Dhule, Maharashtra, India

    Bharti D. Shewale

Authors
  1. Vaishali A. Kilor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nidhi P. Sapkal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jasmine G. Awari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bharti D. Shewale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vaishali A. Kilor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kilor, V.A., Sapkal, N.P., Awari, J.G. et al. Development and Characterization of Enteric-Coated Immediate-Release Pellets of Aceclofenac by Extrusion/Spheronization Technique Using κ-Carrageenan as a Pelletizing Agent. AAPS PharmSciTech 11, 336–343 (2010). https://doi.org/10.1208/s12249-010-9389-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-010-9389-9

Key words

Search

Navigation